MedTrace Logo

Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice

NCT07615166 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2026-05-29

No results posted yet for this study

Summary

The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.

Conditions

Interventions

DRUG

Alirocumab 150 mg

The study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.

DRUG

Inclisiran

The study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-22
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07615166 on ClinicalTrials.gov